This study has been designed to understand more about the day to day impact psoriasis has on the life of patients being treated with secukinumab. Participation includes completing quality of life surveys are your normal visits to see the effect of treatment.
We, here at the Royal Melbourne Hospital, are currently running a non-interventional research study for people who suffer with Hidradenitis Suppurativa, Pyoderma Gangrenosum or Palmoplantar Pustulosis. All of these conditions fall under the umbrella of neutrophilic skin conditions or diseases.
This research project aims to develop test methods to use in a future clinical trial for testing possible new treatments for patients with neutrophilic skin conditions or diseases, and to find out more about the causes of these conditions.
This post-market study involves collecting information for an already approved VNS device. This type of study is conducted for many medications or medical devices to get detailed information about the outcomes of people receiving an approved treatment.
People participating in this study must be deemed appropriate for VNS treatment by their treating doctors and be planned for surgery at The Royal Melbourne Hospital.
The purpose of this study is to better understand the following areas of health for people who receive VNS treatment:
- Anti-epileptic treatment and medication taken by people who have had a VNS device implanted
- Frequency and severity of seizures
- Quality of life and quality of sleep (reported through questionnaires)
- What types of healthcare services are being used
- Details of the settings used on the VNS device
The research study is testing a new treatment for vascular dementia (VaD) and Alzheimer’s disease with cerebrovascular disease. The new treatment is called Sailuotong (SLT). SLT is an extract of three standardised Chinese herbs, Ginseng, Ginkgo and Saffron, all of which are individually permitted for over-the-counter sale in Australia.
The primary objective is to determine the effectiveness of the herbal intervention on cognitive function (the brain functions relating to attention, memory, judgement, reasoning, problem solving etc.), activities of daily living and quality of life, and monitor the safety and effectiveness of SLT.
The purpose of this study is to compare the effects of MTAU9937 versus placebo on participants with Alzheimer’s Disease. MTAU9937 is an antibody, a special molecule in the blood and tissue that can attach to other molecules. MTAU9937 attaches to different forms of a protein called tau. It is believed that certain forms of tau in the brain are involved in the development of Alzheimer’s Disease.
The investigational medication or placebo is given as an intravenous infusion into a vein. Participants will receive the first 3 doses once every 2 weeks and all other doses once every 4 weeks for 68 weeks in total. After this, participants may choose to take part in the extension period for 96 weeks, where all participants will receive active medication only - no placebo - once every 4 weeks.
The total amount of time you could be in the study is approximately 3.5 years if you choose to complete all parts of the study, including the optional extension period.
A gluten-free diet is the only current treatment for coeliac disease but it is complex and not always effective. Even patients who strictly adhere to it can suffer short and long-term adverse effects from gluten exposure.
We are seeking participants for a study testing a new experimental treatment for coeliac disease called Nexvax2. It is a Phase 2 double-blind, randomized, placebo-controlled, multicentre study. The study consists of 3 periods: a screening period of 6 weeks, an approximately 16 week treatment period, and a 4 week observational follow-up period.
This research project is testing a new treatment for locally advanced or metastatic ER-positive breast cancer. The new treatment is called venetoclax given in combination with fulvestrant and we we want to know whether adding venetoclax will add to the effectiveness of the fulvestrant.
Fulvestrant is a drug that is designed to bind to the oestrogen receptors, completely blocking the ability of oestrogen to attach to these receptors. This can help to slow down the growth of ER-positive breast cancer.
Venetoclax has been approved for treatment of a type of leukaemia. In this study, venetoclax is an experimental drug, which means health authorties have not approved it in combination with fulvestrant for the treatment of ER-positive breast cancer.